GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » ROC (Joel Greenblatt) %

Dyax (DYAX) ROC (Joel Greenblatt) % : -638.32% (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is Dyax ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Dyax's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was -638.32%.

The historical rank and industry rank for Dyax's ROC (Joel Greenblatt) % or its related term are showing as below:

DYAX's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -334.375
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Dyax's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Dyax ROC (Joel Greenblatt) % Historical Data

The historical data trend for Dyax's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyax ROC (Joel Greenblatt) % Chart

Dyax Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -499.86 -705.54 -367.76 -330.16 -16.77

Dyax Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.27 30.39 -333.52 -475.56 -638.32

Competitive Comparison of Dyax's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Dyax's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyax's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyax's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Dyax's ROC (Joel Greenblatt) % falls into.



Dyax ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.938 + 3.344 + 4.8340000000001) - (18.207 + 3.856 + -3.5527136788005E-15)
=-2.9469999999999

Working Capital(Q: Sep. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(13.178 + 14.546 + -3.451) - (24.799 + 3.743 + 3.5527136788005E-15)
=-4.269

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Dyax for the quarter that ended in Sep. 2015 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2015 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2015  Q: Sep. 2015
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-33.1/( ( (5.158 + max(-2.9469999999999, 0)) + (5.213 + max(-4.269, 0)) )/ 2 )
=-33.1/( ( 5.158 + 5.213 )/ 2 )
=-33.1/5.1855
=-638.32 %

Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyax  (NAS:DYAX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Dyax ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Dyax's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyax (DYAX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
David J Mclachlan other: Former director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen officer: CEO and President, other: Former director DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore officer: EVP & Chief Commercial Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner other: Former director C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker other: Former director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin other: Former director
Andrew D. Ashe officer: General Counsel & EVP C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen other: Former director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray other: Former director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky officer: EVP & Chief Financial Officer C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci other: Former director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman officer: CMO & EVP, R&D DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch officer: EVP; Chief Operating Officer 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker officer: EVP and CFO 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139

Dyax (DYAX) Headlines

From GuruFocus

Dyax Corp. Reports Operating Results (10-K)

By gurufocus 10qk 03-02-2011

Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 09-15-2010

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 05-03-2016

Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares

By GuruFocus Research GuruFocus Editor 08-25-2010

Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 03-15-2011

Meridian Funds Comments on Dyax Corp

By Holly LaFon Holly LaFon 03-07-2016

Mario Gabelli Comments on Dyax Corp

By Holly LaFon Holly LaFon 01-29-2016